Predicting Clinical Neurotoxicity Using Functional Organoids

In this webinar, weโ€™ll explore the challenges that have historically hindered progress in neurotherapeutics and showcase AxoSimโ€™s suite of advanced neuro platforms designed to tackle these issues head-on.

What Youโ€™ll Learn:

  • An overview of AxoSimโ€™s three neuro platforms, including their unique hallmarks and use-cases for safety and efficacy testing.
  • A deep dive into AxoSimโ€™s functional brain organoid platform, featuring consistent spontaneous network activity, a hallmark that enables robust predictive capabilities.
  • Insights into the development of a predictive neurotoxicity assay aimed at reducing failures caused by CNS toxicity and seizure liability.
  • A case study demonstrating the platformโ€™s application in Rett Syndrome drug discovery, highlighting how AxoSimโ€™s human 3D organoid model delivers critical insights into safety and efficacy.

Speaker

Andrew LaCroix, PhD

Andrew LaCroix is a Lead Scientist at AxoSim specializing in the development of iPSC-derived brain organoid models and their applications to preclinical safety and efficacy testing. Specifically, he has focused on predictive neurotoxicity assays and human-first drug discovery to reduce clinical failure rates and improve patient outcomes.